• All
  • Financials
  • Insiders
Webull provides the latest Monte Rosa Therapeutics, Inc. (GLUE) stock and general news. This information may help you make smarter investment decisions.
About GLUE
Monte Rosa Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called QuEEN, that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. It utilizes its Quantitative and Engineered Elimination of Neosubstrates (QuEEN), platform to design novel MGDs focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways across clinical indications in oncology and non-oncology, including immunology, inflammation, neurological and genetic diseases.